抗EGFR单抗在转移性结直肠癌中耐药机制的研究进展

Research progress of resistance mechanisms and restoring sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

抗表皮生长因子受体(EGFR)单克隆单抗分子靶向药物在转移性结直肠癌中的应用,显著改善了患者无进展生存期及总生存期,由于迅速产生继发性耐药限制了其临床运用效果。因此,寻找生物标志物初步筛选敏感人群及预测耐药,以及研究分子靶向药物耐药机制的产生以逆转耐药,都是进一步提高转移性结直肠癌治疗效果的关键,目前靶向药物联合应用有望进一步提高治疗有效率并逆转耐药。

Epidermal growth factor receptor（EGFR） targeted monoclonal antibodies are effective in a subset of solid tumors incuding metastatic colorectal cancer.While patients develop drug resistance rapidly that limits these agents further clinical treatment.It is important to evalute molecular markers identifying those who are more likely to respond,and it is critical to understand the mechanisms of resistance to targeted therapies.Incorporation of targeted agents has been expected to develop novel therapeutic strategies improving efficacy of colorectal cancer treatment and restoring their drug sensitivity.